Professor Karina Butler:

Other advice will be coming from the EMA this week that may help inform on whether there is a specific age profile that might help define the risk more clearly. The other factors that go into this include what the overall impact on the programme is. Of course, we have heard from Dr. Henry and Mr. McCallion today that there may be more Pfizer supplies. The questions include what will be the overall impact on the programme and where Janssen is needed or might not be needed. Everything has to be taken in the round before a decision can be made.